Maintenance Fedratinib to Prevent Post-Transplant Relapse in

See also
Status	Clinical Trial	Phase
Completed	`NCT04022785` - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Phase 1
Not yet recruiting	`NCT05440838` - Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Completed	`NCT03941769` - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II	Phase 1/Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT03589729` - Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Phase 2
Completed	`NCT04605211` - A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors	N/A
Active, not recruiting	`NCT03588078` - Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Phase 1/Phase 2
Recruiting	`NCT05521204` - Olverembatinib for FGFR1-rearranged Neoplasms	Phase 2
Enrolling by invitation	`NCT04994158` - MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
Completed	`NCT04192916` - Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Not yet recruiting	`NCT03177928` - Cardiac Changes in Myeloproliferative Neoplasms	N/A
Recruiting	`NCT05419648` - Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
Recruiting	`NCT04955938` - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Phase 1
Recruiting	`NCT04942080` - Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)	N/A
Completed	`NCT04146038` - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Phase 2
Not yet recruiting	`NCT06468033` - P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk	Phase 3
Completed	`NCT02862366` - Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-
Not yet recruiting	`NCT06022341` - MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies	N/A
Recruiting	`NCT03630991` - Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Phase 1

NCT number	NCT05127174
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact	Maria Urdiales
Phone	813-745-1218
Email	Maria.Urdiales@moffitt.org
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 14, 2022
Completion date	November 2025

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms